You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞銀窩輪》藥明生物(02269)週二急瀉 資金流入好倉博反彈 看好留意藥明認購(17209)
「618」購物節剛過,人民幣雙櫃台模式亦已於週一實行,中國亦下調6月貸款市場報價利率(LPR )10點子,可惜多重利好消息未能帶給股市動力。週二恆指險守250天線,成交未足一千億。根據瑞銀即市資金流資料,牛熊比例大概為4.5:5.。如投資者看好恆指,可留意恆指認購(14178),行使價22000點,23年9月到期,有效槓桿約16.7倍。如投資者看好恆指,可留意恆指牛證(66314),收回價19150點,25年7月到期,有效槓桿約34倍。如投資者看淡恆指,可留意恆指認沽(12248),行使價18350點,23年9月到期,有效槓桿約12倍。如投資者看淡恆指,可留意恆指熊證(67189),收回價20068點,25年11月到期,有效槓桿約38.9倍。 人民幣雙櫃台模式已於週一實行,首批24隻港股週一全日成交近1.8億元,加上整體6月份港幣成交亦偏弱,根據瑞銀即市資金流資料,週二資金一面倒睇淡港交所(00388)。如投資者看淡港交,可留意港交認沽(15553),行使價269.8港元,23年9月到期,有效槓桿約11.3倍。如投資者看淡港交,可留意港交熊證(61276),收回價345港元,24年2月到期,有效槓桿約8.4倍。人民幣雙櫃台模式始終較新,如憧憬人民幣雙櫃台成交會隨著時間增多,如投資者看好港交,可留意港交認購(26819),行使價333.53港元,23年9月到期,有效槓桿約11.6倍。如投資者看好港交,可留意港交牛證(66020),收回價285港元,23年10月到期,有效槓桿約11.4倍。 藥明生物(02269)週二急瀉17%,午市跌幅較急時不少資金流入好倉博反彈。如投資者看好藥明,可留意藥明認購(17209),行使價58.63港元,24年7月到期,有效槓桿約3.1倍。如投資者看好藥明,可留意藥明牛證(64928),收回價34港元,23年10月到期,有效槓桿約5.6倍。 更多窩輪牛熊資訊:瑞銀認股證牛熊證網站: http://www.ubs.com/hkwarrants 輪證教學及巿況焦點短片: https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber 瑞銀認股證牛熊證團隊 本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人),並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發,其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌,投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止,屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險,並諮詢專業顧問及查閱有關上市檔。UBS Securities Hong Kong Limited為結構性產品之流通量提供者,亦可能是唯一報價者或巿場參與者。(C) UBS 2023。版權所有。~ 重要聲明: 以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account